Belpointe Asset Management’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Belpointe Asset Management’s Portfolio IHE Stock Details IHE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,827	Closed	-$107K	–	1880
2023 Q1	$107K	Sell	1,827 -294	-14%	-$17.7K	0.01%	1266
2022 Q4	$132K	Sell	2,121 -378	-15%	-$22.7K	0.01%	1094
2022 Q3	$141K	Buy	2,499 +6	+0.2%	+$370	0.01%	987
2022 Q2	$159K	Sell	2,493 -1,914	-43%	-$122K	0.01%	914
2022 Q1	$285K	Sell	4,407 -141	-3%	-$8.94K	0.02%	752
2021 Q4	$303K	Sell	4,548 -156	-3%	-$9.89K	0.02%	704
2021 Q3	$287K	Buy	4,704 +186	+4%	+$11.8K	0.02%	701
2021 Q2	$280K	Buy	4,518 +15	+0.3%	+$912	0.02%	698
2021 Q1	$267K	Sell	4,503 -588	-12%	-$35.5K	0.02%	631
2020 Q4	$305K	Buy	5,091 +3,264	+179%	+$186K	0.03%	551
2020 Q3	$100K	Buy	+1,827	New	+$98.5K	0.01%	773

Other funds holding IHE

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

RIG

RiverFront Investment Group Richmond, Virginia $6.46B AUM 18.45% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

Belpointe Asset Management's IHE Position: Q2 2023 in Review

Belpointe Asset Management sold out of iShares US Pharmaceuticals ETF (IHE) in Q2 2023, closing a stake of 1,827 shares — an estimated $107K sold.

Belpointe Asset Management first reported a position in IHE in Q3 2020 and held it in 11 quarters. The position peaked at $305K in Q4 2020. 120 funds tracked by Wall St. Rank hold IHE as of Q2 2023.

Belpointe Asset Management reported no remaining iShares US Pharmaceuticals ETF position as of Q2 2023 after selling out during the quarter.
Belpointe Asset Management sold 1,827 iShares US Pharmaceuticals ETF shares in Q2 2023, an estimated $107K.
Belpointe Asset Management first reported a position in iShares US Pharmaceuticals ETF in Q3 2020 and held it in 11 quarters.
Belpointe Asset Management's iShares US Pharmaceuticals ETF position peaked at $305K in Q4 2020.
120 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.